Viridian Therapeutics (VRDN) closed at $28.49 on November 6, 2026, down 0.2% from the previous close, on volume of 4,139,711 shares (30-day average 2,347,576).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 6, 2026 | Call Spread | 20-Nov-2623 : 30 C | 500 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Business Wire (Fri, 6-Nov 4:01 PM ET)
TipRanks (Fri, 6-Nov 8:50 AM ET)
Viridian Therapeutics (VRDN) Receives a Buy from Leerink Partners
TipRanks (Thu, 5-Nov 9:30 AM ET)
RBC Capital Keeps Their Buy Rating on Viridian Therapeutics (VRDN)
TipRanks (Thu, 5-Nov 7:39 AM ET)
Analysts Are Bullish on These Healthcare Stocks: Seres Therapeutics (MCRB), Nuvectis Pharma (NVCT)
TipRanks (Wed, 4-Nov 12:10 PM ET)
VRDN highlights $24.7M Lumvoa launch quarter as multiple 2026–2027 milestones line up
Market Chameleon (Wed, 4-Nov 2:53 AM ET)
Viridian Therapeutics GAAP EPS of -$0.81 beats by $0.21, revenue of $24.7M beats by $19.98M
Seeking Alpha News (Wed, 4-Nov 7:28 AM ET)
Business Wire (Wed, 4-Nov 7:01 AM ET)
Analysts’ Top Healthcare Picks: Viridian Therapeutics (VRDN), Idexx Laboratories (IDXX)
TipRanks (Tue, 3-Nov 9:30 PM ET)
Viridian Therapeutics Q3 2026 Earnings Preview
Seeking Alpha News (Tue, 3-Nov 11:51 AM ET)
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
Viridian Therapeutics trades on the NASDAQ stock market under the symbol VRDN.
As of November 6, 2026, VRDN stock price declined to $28.49 with 4,139,711 million shares trading.
VRDN has a beta of -0.80, meaning it tends to be less sensitive to market movements. VRDN has a correlation of 0.02 to the broad based SPY ETF.
VRDN has a market cap of $3.24 billion. This is considered a Mid Cap stock.
Last quarter Viridian Therapeutics reported $25,752 in Revenue and -$.81 earnings per share. This fell short of revenue expectation by $-5 million and exceeded earnings estimates by $.21.
In the last 3 years, VRDN traded as high as $34.29 and as low as $9.90.
The top ETF exchange traded funds that VRDN belongs to (by Net Assets): IWM, XBI, VTI, VXF, IWN.
VRDN has underperformed the market in the last year with a return of +3.6%, while SPY returned +10.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in VRDN shares. However, VRDN has outperformed the market in the last 3 month and 2 week periods, returning +26.6% and +27.4%, while SPY returned -4.1% and -3.2%, respectively. This indicates VRDN has been having a stronger performance recently.
VRDN support price is $27.50 and resistance is $29.60 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VRDN shares will trade within this expected range on the day.
